Transaction · 0001193125-26-443732

Thomson Todd S

THOMSON TODD S, DIR, reported a transaction classified as grant at ACTUATE THERAPEUTICS, INC. involving 259572.000000 shares. Reported holdings after the transaction were 259572.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
ACTUACTUATE THERAPEUTICS, INC.
Trade date
Oct 28, 2026
Filing date
Nov 02, 2026
View on SEC Insider profile
Disclosed valueUnknownShares × reported price
Shares traded259kPrice unknown
Holdings after259kIndirect · By Kairos Venture Opportunities I, L.P.
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ACTU price since this filing

Daily closing prices, with the filing date and available return windows
ACTU · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +117.6%1w ago +64.7%1d ago +17.6%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001193125-26-443732
Warrants (right to buy)
Transaction date
Oct 28, 2026
Filed Nov 02, 2026, 09:27 PM · 5d delay
Shares
259,572 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
259,572 sh
Indirect · By Kairos Venture Opportunities I, L.P.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-24 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P.,…

  2. F2

    Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disc…

  3. F3

    In consideration for an agreement between Actuate and the Kairos Funds pursuant to which the Kairos Funds agreed, subject to certain limited exceptions, not to sell, transfer or dispose of, directly o…

  4. F4

    The Warrants were immediately exercisable upon issuance and expire five years after the closing of the Offering.

Original filing · 0001193125-26-443732
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ACTU